[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-obstructive-lung-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-obstructive-lung-disease":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,38,76,102,129,152,177,208,234],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":4},"100640199","screening-for-obstructive-respiratory-disorders-in-the-general-population-during-the-mai-poumon-2026-prevention-campaign-prevalence-and-impact-on-the-care-pathway-100640199",false,"NCT07575880","Screening for Obstructive Respiratory Disorders in the General Population During the \"Mai Poumon 2026\" Prevention Campaign: Prevalence and Impact on the Care Pathway","Mai Poumons 26","* Inclusion criteria :\n* Age ≥ 18 years\n* Participating to the prevention campain \"Mai Poumons 2026\" on 09 Mai 2026\n* Exclusion criteria :\n* Contre-indication to perform a spirometry : hemoptysy, pneumothorax, myocardal infarction \\\u003C1month, thoracic anevrism, recent ophtalmologic, abdominal or thoracic surgery\n* Unable to perform a spirometry (understanding, coordination)\n* Patient under legal protection\n* Patient pregnant or breasting\n* Not affiliating to public healthcare\n* Patient deprived of liberty","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Undiagnosed COPD represents a significant issue in terms of morbidity and mortality, as nearly 50% of smokers with chronic respiratory symptoms also experience impaired quality of life and acute events similar to COPD exacerbations. We aim to study the prevalence of airflow obstruction (AO) and PRISm (preserved ratio impaired spirometry) in the general population.",[24,25],"Chronic Obstructive Lung Disease","Airflow Obstruction","NOT_YET_RECRUITING","2026-05-11",{"date":29,"type":30},"2026-05-13","ACTUAL",{"date":32,"type":20},"2026-05-09",{"date":34,"type":20},"2026-12",{"name":36,"class":37},"Centre Hospitalier de la côte Basque","OTHER",{"id":39,"slug":40,"hasResults":11,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":48,"phases":49,"briefSummary":51,"conditions":52,"keywords":54,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100628389","singing-training-vs-usual-care-6-18-months-after-surgical-resection-for-non-small-cell-lung-cancer-nsclc-100628389","NCT07460999","Singing Training vs Usual Care 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC)","Effects and Mechanisms of Online Delivered Singing Training vs Usual Care in Patients With Persistent Symptoms 6-18 Months After Surgical Resection for Non-small Cell Lung Cancer (NSCLC) - a Multi-centre RCT","Sing-a-Lung 2","Inclusion Criteria:\n\nPatients who display persistent symptoms 6-18 months (+\u002F- one month) after surgical resection of localised lung cancer with video-assisted thoracoscopy (VATS) will be invited to participate in the study.\n\nInclusion criteria for the study include:\n\n1. Persistent symptoms, i.e., an EORTC-QLQ-C30 symptom domain score (in any item) of ≥2 (=\"clinically relevant symptom or problem that should have healthcare professional attention\"),\n2. Surgery for stage I lung cancer 6-18 months (+\u002F- one month) earlier,\n3. Motivated for participating in the project (and acceptance of randomisation procedure),\n4. Access to a computer or a tablet with internet access,\n5. Ability to speak and understand Danish,\n6. Acceptance of the scheduled times of the singing intervention twice a week.\n\nExclusion Criteria:\n\nExclusion criteria include:\n\n1. Unstable coronary diseases,\n2. Severe cognitive disabilities (e.g., dementia),\n3. Indication for adjuvant chemotherapy or other antineoplastic therapy,\n4. Signs of lung cancer recurrence at regular follow-up CT scan.\n\nNo previous singing experience or musical competence is required. Participants will be informed that they are allowed to participate in additional offer of structured or unstructured offer physical exercise training and\u002For singing along with the project.",{"count":47,"type":20},100,"INTERVENTIONAL",[50],"NA","People who have undergone curative surgery for non-small cell lung cancer (NSCLC) often experience reduced quality of life (QoL), a high burden of symptoms, and physical deconditioning. Current Danish rehabilitation offers are heterogeneous and inconsistent and not tailored to the specific needs of this population. Additionally, some patients continue to suffer from persistent physical symptoms months or even years after surgery, yet no targeted support is currently available for them. Singing - delivered as a structured form of training - has shown benefits in improving both physical and psychological outcomes in individuals with chronic obstructive pulmonary disease (COPD). Although singing has not yet been studied in NSCLC patients, the two conditions share overlapping symptoms and characteristics. Therefore, the present study aims to explore whether a singing-based intervention can help reduce symptom burden and improve physical function and QoL in NSCLC patients 6 to 18 months post-surgery. To test this, a multi-centre randomised controlled trial (RCT) will be conducted, comparing a singing intervention to usual care. Given that travel and distance often pose significant barriers to participation, the intervention will be delivered online.",[53,24],"Non-Small Cell Lung Cancer",[55,56,57,58,59,60,61,62,63,64],"lung cancer","rehabilitation","singing","online training","physical capacity","quality of life","symptom burden","airway physiology","physiology","six-minute walk test","RECRUITING","2026-03-27",{"date":68,"type":30},"2026-04-02",{"date":70,"type":30},"2026-03-01",{"date":72,"type":20},"2027-10-01",{"name":74,"class":37},"Zealand University Hospital",5,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":84,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":48,"phases":88,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":98,"locationsCount":101},"100591872","phase-1-investigation-of-small-mobile-stem-cells-sms-cells-in-participants-with-chronic-obstructive-pulmonary-disease-copd-100591872","NCT06986070","Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD).","A Phase 1, First-in-Human, Clinical Trial to Evaluate the Safety of Small Mobile Stem Cells (SMS) Delivered Into the Lung as a Potential Organ Regeneration Therapy in Chronic Obstructive Pulmonary Disease (SORT-COPD Study","SORT-COPD","Inclusion Criteria:\n\n1. Aged 39 to 69 years (inclusive).\n2. Female participants:\n\n   A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:\n\n   Is a woman of nonchildbearing potential (WONCBP) OR Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method from screening until 30 days after the last dose of study intervention.\n\n   A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) at Screening and on Day 1, prior to administration of study intervention.\n\n   If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.\n\n   The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n3. Male participants:\n\n   Male participants are eligible to participate if they agree to the following during the study intervention period and for at least 30 days after the last dose of study intervention:\n\n   Refrain from donating fresh unwashed semen. Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR must agree to use contraception\u002Fbarrier (male condom).\n4. Has a diagnosis of mild or moderate COPD-C (cigarette smoking COPD) or COPD-P (biomass and pollution exposure COPD) according to the 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Criteria.\n\n   Lung impairment will be determined with post-bronchodilator FEV1 spirometry.\n5. Has previously received treatment for COPD-C or COPD-P.\n6. Has stable COPD disease state, defined as no exacerbations in the 12 weeks prior to screening, no hospitalizations in the 12 weeks prior to screening, and no changes in COPD medication in the 28 days prior to screening.\n7. Agrees to comply with study specific procedures and visits, including non-smoking during the treatment and follow-up periods of the study.\n8. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Previous or current diagnosis of COPD-G, COPD-D, COPD-I, COPD-A or COPD-U; asthma, congestive heart failure, bronchiectasis, tuberculosis, obliterative bronchiolitis or diffuse panbronchiolitis.\n2. Previous or current history of respiratory failure other than due to COPD (e.g. restrictive lung disease, sarcoidosis, tuberculosis, idiopathic pulmonary fibrosis, bronchiectasis, CMV pneumonitis, cystic fibrosis, asbestosis, silicosis or farmer's lung disease), or detection of any of these conditions through screening CT scanning.\n3. History of COVID associated pneumonia with hypoxemic respiratory failure in the 12 weeks prior to screening.\n4. Current use, or use within 21 days of screening, of systemic corticosteroids. Participants on inhaled corticosteroids or combined inhaled therapies can be included, however must schedule inhaled therapies 12 hours prior to dosing IP and 12-hours post dosing IP.\n5. Any history of chronic liver disease, or abnormal liver function at screening, defined as:\n\n   Alanine transaminase (ALT) and\u002For aspartate aminotransferase (AST) more than 2.5 times the upper limit of normal (ULN) Total bilirubin more than two times the ULN Participants with documented Gilbert's syndrome are permitted to enter the study.\n6. History of chronic renal insufficiency, defined as and eGFR \\\u003C 90 mL\u002Fmin\u002F1.73 m2. Participants without a history of chronic renal insufficiency, who at screening have an eGFR detected between 60-89 mL\u002Fmin\u002F1.73 m2, should have their eGFR repeated as per standard clinical procedure.\n7. Uncontrolled hypertension, or current hypertension controlled on more than two medications.\n8. History, within the last two years, of coronary artery disease, coronary artery bypass graft surgery, percutaneous transluminal coronary angioplasty, severe peripheral arterial disease, cerebrovascular disease (including history of transient ischemic attack or cerebrovascular accident), or any such history that, in the opinion of the investigator, will impact participation in the study.\n9. Type 1 or Type 2 diabetes mellitus with glycosylated hemoglobin (HbA1c \\> 7.5%) at screening.\n10. No active malignancy in the last three years, including any potential neoplasm detected via high-resolution CT scan (nodule \\> 5 mm) detected as part of the screening process.\n\n    People with a history of basal cell or squamous cell carcinoma of the skin are eligible.\n11. History of HIV or other immunosuppressed conditions, Hepatitis B or Hepatitis C, or use of immunosuppressive medications within 14 days prior to screening, and for 3 weeks after the last dose of study intervention is administered.\n12. Active infection requiring systemic antibiotic treatment within 12 weeks prior to screening.\n13. Body mass index (BMI) \\> 60 kg\u002Fm2.\n14. Active smoking of tobacco, cannabis or vaping in the 28 days prior to screening as indicated by results of cotinine urine testing, performed at screening. Use of nicotine containing products such as nicotine patches, oral nicotine products or nicotine chewing gum is permitted, noting that cotinine results will be positive. Positive results will be documented by the investigator as \"attributed to permitted nicotine products\".\n15. History of alcohol or other substance abuse, with sobriety less than one year, or that in the opinion of the investigator, will impact participation in the study.\n16. Pregnant or breastfeeding.\n17. Any severe medication allergy, including an allergy to bovine products.\n18. Any other medical condition, psychiatric condition or illness, that according to the Principal Investigator might render the subject unlikely to tolerate the inhalation of SORT-COPD (SMS cells), or to complete the study.\n19. Current participation in any other clinical trial or participation in the last six weeks or subject received an experimental therapy (drug or biologic) for any indication within 12 months prior to enrolment.\n20. Unable or unwilling to comply with study specific schedules or procedures.","39 Years","69 Years",{"count":87,"type":20},18,[89],"PHASE1","This study is a phase 1, first-in-human, open-label, non-randomized, dose escalation safety study of 18 participants, between 39 and 69 years of age, with mild to moderate chronic obstructive pulmonary disease, treated with SORT-COPD (SMS cells).\n\nThe primary objective of this study is to determine the safety of SORT-COPD (SMS cells) at three doses in people with chronic obstructive pulmonary disease.",[24],"2026-02-09",{"date":94,"type":30},"2026-02-12",{"date":96,"type":30},"2025-06-13",{"date":34,"type":20},{"name":99,"class":100},"SMSbiotech","INDUSTRY",2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":48,"phases":112,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100616891","improvement-of-sleep-in-copd-patients-through-inhalation-management-education-by-nurse-100616891","NCT07311499","Improvement of Sleep in COPD Patients Through Inhalation Management Education by Nurse.","A Study on Improving Sleep Quality in COPD Patients Through Inhalation Management Education by Nurses Using Video Conferencing Tools.","Inclusion Criteria:\n\n* Individuals aged 20 years or older at the time of consent.\n* Individuals who have been prescribed inhaled medications and have been using them continuously for more than one month.\n* Prior experience with inhalation instruction is not required.\n* Individuals who have not been hospitalized within one month prior to study participation due to exacerbation of COPD.\n* Individuals with obstructive sleep apnea syndrome (OSAS) who are receiving treatment with continuous positive airway pressure (CPAP) therapy are eligible, provided that the physician determines that symptoms are stable following CPAP initiation.\n* Participants must be able to operate devices such as Android, iPad, or computer. However, if a caregiver can operate the device, the participant's inability to do so is acceptable.\n* Participants must be in a stable condition as determined by a physician and have obtained permission to participate.\n\nExclusion Criteria:\n\n* Suffering from other respiratory diseases such as asthma or interstitial pneumonia\n* Suffering from advanced cancer, including lung cancer\n* Restricted chest movement due to chest deformity or trauma\n* Suffering from diseases that cause respiratory distress, such as heart disease\n* Suffering from sleep-disordered breathing with a central AHI of more than 50%\n* Diagnosed with dementia or mental illness","20 Years",{"count":111,"type":20},60,[50],"This study aims to investigate whether inhalation management education provided by nurses improves sleep quality in patients with COPD. Inhalation management education includes training in inhalation techniques and guidance on how to use medications when symptoms occur.\n\nThe main research question is:\n\n・Does inhalation management education improve sleep quality in patients with COPD?\n\nResearchers will determine whether inhalation management education improves sleep quality compared to no education.\n\nParticipants will:\n\n* Participate in two interviews with researchers using video conferencing tools.\n* Keep a diary recording their symptoms, sleep duration, and the frequency of rescue inhaler use.",[24],[116,117,118],"COPD","inhalation management education","sleep quality","2025-12-21",{"date":121,"type":30},"2025-12-31",{"date":123,"type":20},"2026-01",{"date":125,"type":20},"2029-03-31",{"name":127,"class":37},"Kumamoto University",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":48,"phases":138,"briefSummary":139,"conditions":140,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100456742","mapping-and-characterization-of-alveolar-cells-during-smoking-and-chronic-obstructive-disease-100456742","NCT05227547","Mapping and Characterization of Alveolar Cells During Smoking and Chronic Obstructive Disease","CoStemCells","Inclusion Criteria:\n\n1. Age ≥ 18\n2. Patient undergoing lung resection surgery (lobectomy, pneumonectomy, segmentectomy) for cancer or suspected cancer\n3. Acceptance to participate in the protocol\n4. Affiliated to a social security plan\n\nExclusion Criteria:\n\n1. Chronic autoimmune disease\n2. Patient under guardianship or curators\n3. Neo-adjuvant chemotherapy\n4. History of thoracic radiotherapy\n5. Pregnant woman\n6. Minor patient\n7. Person not able to consent\n8. Person deprived of liberty",{"count":137,"type":20},186,[50],"To evaluate the regenerative capacities of mesenchymal cells composing the microenvironment of alveolar type 2 cells in a population of patients, undergoing thoracic surgery for suspected cancer, who are smokers with and without COPD compared to non-smokers patients",[24,141],"Chronic Obstructive Pulmonary Disease","2025-08-26",{"date":144,"type":30},"2025-09-02",{"date":146,"type":30},"2022-10-05",{"date":148,"type":20},"2030-10-05",{"name":150,"class":37},"Centre Hospitalier Intercommunal Creteil",4,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":48,"phases":162,"briefSummary":163,"conditions":164,"keywords":165,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":128},"100594113","effects-of-virtual-reality-assisted-dual-task-training-on-muscle-oxygenation-in-patients-with-copd-100594113","NCT07015216","Effects of Virtual Reality-Assisted Dual Task Training on Muscle Oxygenation in Patients With COPD","Investigation of the Effects of Virtual Reality-Assisted Dual Task Training on Cerebral, Peripheral, and Respiratory Muscle Oxygenation in Patients With Chronic Obstructive Pulmonary Disease","Inclusion Criteria:\n\n* Diagnosis of COPD stage 2 or 3 according to GOLD classification\n* No orthopedic and\u002For neuromuscular conditions that would interfere with dual-task training\n* Ability to ambulate\n* Adequate cognitive level to participate in the training (Mini Mental State Examination score ≥ 23)\n* Voluntary participation\n\nExclusion Criteria:\n\n* Presence of vestibular problems that would interfere with virtual reality applications\n* Visual impairments\n* Any medical condition contraindicating exercise participation\n* Being in an acute exacerbation period\n* Having an active infection\n* Diagnosis of cancer\n* Known cardiovascular disease","70 Years",{"count":161,"type":20},30,[50],"Chronic Obstructive Pulmonary Disease (COPD) is a common but preventable disease that is associated with a chronic inflammatory response in the airways and lungs to noxious gases, often progressive, resulting in a persistent limitation of airflow. Chronic cough, dyspnea, and sputum production are the most common symptoms of the disease. Respiratory failure and decrease in physical activity seen in the later stages of the disease also negatively affect the participants' participation in daily life. COPD, which is an important health problem due to its increasing incidence, high prevalence, and associated social and economic costs, ranks fourth among the global causes of death.\n\nCognitive and physical impairments are often associated with COPD prognosis. In the literature, a relationship was found between prefrontal cortex activity, exercise tolerance, and dyspnea perception of the individual. The prevalence of cognitive impairment in COPD ranges from 10 to 61%. Considering the effect of cognitive function on motor control, it is thought to affect physical performance. Studies have reported that prefrontal cortex oxygenation and perfusion increase with exercise. Depending on the positive effect of neuron metabolism, increases in cognitive and physical functions are observed.\n\nWhen examining the results of dual-task training and virtual reality applications in geriatric and neurological populations, positive effects on physical and cognitive functions have been demonstrated. Dual-task training causes an increase in cerebral perfusion and oxyhemoglobin as it requires more cognitive resources. Therefore, it is important for the investigators to create a program that includes cognitive performance rather than focusing only on motor performance in the rehabilitation of patients with COPD. Virtual reality applications are also widely used in many areas. A limited number of studies conducted on individuals with COPD have shown positive effects on physical performance. When examining the literature, it is seen that there is no study investigating the effects of virtual reality-assisted dual-task training in individuals with COPD.\n\nBased on this information, the investigators aim to evaluate the effect of virtual reality-supported dual-task training on cerebral, peripheral muscle, and respiratory muscle oxygenation in individuals with COPD using the fNIRS imaging method. The 30 individuals with COPD included in the study will be divided into two groups as intervention and control groups. In addition to the conventional physiotherapy and rehabilitation program, virtual reality-supported dual-task training will be given to the intervention group. In the control group, only the conventional physiotherapy and rehabilitation program will be applied. The treatment program will continue for 6 weeks, 3 days a week in both groups. Within the scope of the project, respiratory muscle strength, respiratory function, peripheral muscle strength, fatigue, balance, functional capacity, activity of daily living, cognitive level, and cerebral, peripheral, and respiratory muscle oxygenation of both groups will be evaluated before and after the intervention, and the effects of the intervention will be examined.\n\nFor these purposes, the study will be the first in the literature to evaluate the effect of virtual reality-supported dual-task training in terms of cognitive functions and oxygenation and compare it with conventional physiotherapy applications.\n\nThe study results will provide a basis for determining an optimal non-pharmacological treatment method to protect and improve physical and cognitive performance in individuals with COPD. In addition, the investigators believe that the study will have a social impact by helping to reduce mortality and morbidity rates in these patients and indirectly alleviate the burden on healthcare services. This project will contribute to the literature by providing a different perspective for clinical applications, as well as serving as a guide for future studies.",[24],[24,166,167],"dual task training","oxygenation","2025-06-17",{"date":170,"type":30},"2025-06-22",{"date":172,"type":20},"2025-07-12",{"date":174,"type":20},"2026-01-10",{"name":176,"class":37},"Istinye University",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":185,"targetDuration":4,"studyType":48,"phases":186,"briefSummary":187,"conditions":188,"keywords":191,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":101},"100564476","make-every-step-count-personalised-music-feedback-to-walking-for-people-living-with-copd-100564476","NCT06629675","Make Every Step Count: Personalised Music Feedback to Walking for People Living With COPD","Personalised Music Feedback to Optimise Adherence to the Walking Exercise Prescription During Pulmonary Rehabilitation for Individuals Living With Chronic Obstructive Pulmonary Disease","MuSiC","Inclusion Criteria:\n\n* Willing and able to provide informed consent for participation in the study.\n* The patient is referred for PR at the UHL.\n* The patient has a confirmed diagnosis of COPD using spirometry (based on GOLD criteria)\n* Male or female, aged 18+ years.\n* Able to communicate in written and spoken English.\n\nExclusion Criteria:\n\n* Unable to provide valid informed consent.\n* Lack of motivation to participate in PR programme.\n* Any-contra-indications absolute or relative to exercise training.\n* Has had a cardiac event within last 6 weeks\n* Severe psychiatric disorders\n* Patients with a history of MRSA +ve screens (patients can be assessed and given an exercise programme but cannot attend the classes. Patients need to have 3 consecutive -ve MRSA swabs before they can attend).\n* Unable to understand written or spoken English.",{"count":161,"type":20},[50],"Pulmonary Rehabilitation (PR) is an evidence-based intervention to effectively manage the physiological and psychological effects of Chronic Obstructive Pulmonary Disease (COPD). The aims of PR are to improve symptoms of COPD, increase exercise capacity, increase independency, improve overall behaviour related to health (like exercising more), and enhance quality of life. The cornerstone of PR programmes is aerobic exercise prescription. Typically, walking exercise is used, and the prescription is individualised for each patient based on their maximal walking exercise capacity. However, adherence to walking exercise is challenging for service users, particularly when unsupervised at home. The use of music during exercise shows promise as a tool to decrease the perception of fatigue and increase motivation, but the integration of music via smartphone applications to support walking exercise adherence during PR has not been explored. This project aims to assess if a new mobile application BeatClearWalker (BCW) intervention is practical, acceptable, and effectively used by people living with COPD. The app is designed to help people living with COPD attending PR adhere to their prescribed walking pace during exercise. The BCW app provides real-time, personalised music feedback through music degradation to optimise the dose of walking exercise.",[189,24,190],"Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Airway Disease",[192,193,194,195,196,197,198],"Auditory feedback","Chronic Obstructive Pulmonary Diseases","Digital Health Technology","Exercise","Exercise adherence","Pulmonary rehabilitation","Mobile applications","2025-04-11",{"date":201,"type":30},"2025-04-16",{"date":203,"type":20},"2025-04-20",{"date":205,"type":20},"2025-09-26",{"name":207,"class":37},"University of Leicester",{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":216,"sex":16,"minAge":17,"maxAge":217,"enrollmentInfo":218,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":219,"conditions":220,"keywords":224,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":230,"leadSponsor":232,"locationsCount":128},"100570920","investigating-oestrogen-signalling-and-the-effect-upon-the-extracelluar-matrix-in-patients-with-obstructive-lung-disease-100570920","NCT06713512","InvEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease","invEstigating oeStrogen Signalling and the Effect upoN the exTracelluar Matrix In pAtients With Obstructive Lung Disease","ESSENTIAL","Inclusion Criteria:\n\n1. Men and women aged \\> 18 years.\n2. For female participants: pre-menopausal, peri-menopausal and post-menopausal women can all be included.\n3. Participants willing and able to give informed consent for participation in the study.\n4. Healthy controls \\<10 pack year history (participants without Asthma or COPD).\n\nExclusion Criteria:\n\n1. Known or suspected current pulmonary tuberculosis, HIV (human immunodeficiency virus), Hepatitis B Virus, Hepatitis C Virus.\n2. Alcohol or recreational drug abuse, is defined as when the use is harmful as per NHS definition.\n3. History of psychiatric, medical, or surgical disorders.\n4. Pregnant\n5. Unable to provide written informed consent\n6. History of advanced medical conditions with an expected prognosis of \\< 3 years.\n7. Patients with a history of active cancer.\n8. Patients on long term oxygen (ambulatory oxygen).",true,"99 Years",{"count":47,"type":20},"This study aims to understand the role of oestrogen in patients with asthma and Chronic Obstructive Pulmonary Disorder (COPD). Therefore, what is the effect of oestrogen in these participants compared to controls (those without disease). The study hypothesises that oestrogen loss in patients with asthma and COPD causes accelerated lung function decline and changes to lung structure. It will investigate if this is mediated by inflammation, immune host response or elastin and collagen changes. It is an observational prospective cohort study aiming to recruit healthy controls, and people with asthma or COPD), and\u002For the menopause.",[24,221,222,223],"Respiratory Ilness","Estrogen Deficiency","Asthma",[223,116],"2024-11-27",{"date":227,"type":30},"2024-12-03",{"date":229,"type":20},"2024-12-01",{"date":231,"type":20},"2028-11-01",{"name":233,"class":37},"Guy's and St Thomas' NHS Foundation Trust",{"id":235,"slug":236,"hasResults":11,"nctId":237,"briefTitle":238,"officialTitle":238,"acronym":239,"eligibilityCriteria":240,"healthyVolunteers":216,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":241,"targetDuration":243,"studyType":21,"phases":4,"briefSummary":244,"conditions":245,"keywords":249,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":128},"100270686","copd-patient-powered-research-network-100270686","NCT02803242","COPD Patient-Powered Research Network","COPD PPRN","Inclusion Criteria:\n\n* 18 years or older that says yes to one of the following:\n* COPD diagnosis\n* Current or former smoker\n* Family history of respiratory disease\n* Symptomatic of respiratory disease\n\nExclusion Criteria:\n\n* Non-English speaking",{"count":242,"type":20},75000,"15 Years","The COPD Patient-Powered Research Network (COPD PPRN) is a patient research registry with the goal of enrolling 75,000 or more COPD patients and those at risk who are willing to share their heath information over several years and participate in research. The COPD PPRN has built an online platform to allow volunteers to enroll electronically, complete surveys, be contacted about studies they qualify for and become connected to COPD resources. The goal of the registry is to speed research to find better treatments for COPD and ultimately a cure.",[246,24,247,248],"Chronic Obstructive Pulmonary Disorder","Emphysema","Chronic Bronchitis",[250,251,252,253],"copd","emphysema","bronchitis","bronchiectasis","2022-03-08",{"date":256,"type":30},"2022-03-10",{"date":258,"type":4},"2014-08",{"date":260,"type":20},"2030-01",{"name":262,"class":37},"COPD Foundation"]